Hundreds of Medical Journals announce that COVID 19 symptoms should be treated as severe Thrombosis

An overwhelming  amount of medical evidence has been published in science and medical journals which are taking the medical community by storm with groundbreaking medical studies published by doctors since the beginning of COVID-19 speading across the world since December 2019, to the date of this article, the 7th of June 2020.

Doctors  in direct contact with patients in emergency units in hospitals all over the world have been publishing hundreds of scientific peer reviewed journals reporting clear evidence that patients with acute symptoms of COVID-19 are displaying severe thrombosis symptoms and should be treated as such.

The COVID-19 pandemic has brought unique challenges to scientific research and has been a medical Earthquake that has shaken up not only Doctors and hospitals but also the world of medical journals along with many research institutions and teams. The fast accumulating  discoveries also means there are a backlog of science journals waiting to be published that have not yet reached  mainstream media or been noticed by government health advisors who are hyperfocused on vaccines, which is puzzling when there are so many of them in the Medical Scientific Journal currently advising safe and mostly successful treatments.

Evaluation of the earliest Wuhan patient data suggests that the coagulopathy with COVID-19 is a result of the inflammatory response to SARS-CoV-2 infection resulting in thromboinflammation and driving thrombosis

These Medical findings have been learned in ICU emergency units on the frontline by doctors all over the world, from China, to the US to the Netherlands, Germany, Canada, India, UK, Italy, Pakistan, Russia etc. However, presently as governments are not highlighting these findings and seem to be focused on vaccine production, meanwhile, present lives could be saved with following the current medical consensus, which is to treat  COVID-19 patients in critical condition for Thrombosis and Inflammation.

The results  correlate that the high incidence of thromboembolic events in these patients, suggests an important role of COVID-19–induced coagulopathy.  This means it causes disseminated intravascular coagulation swelling of veins, tissue and cell damage, and bleeding. This condition affects the lungs primarily because they become inflamed. However, the inflammation extends to other organs in the body, such as the liver, kidneys, heart and the infection induces thrombosis through a complex but well-known pathophysiological mechanism.  Consequently, this can cause pneumonia like symptoms, heart attack, stroke and many other thromboembolic related diseases.

A recent medical journal published on this was in the Journal of Thrombosis Research,  where eleven doctors contributed to the study. Doctors from the Netherland performed studies on 184 patients with proven COVID-19 pneumonia, of whom 23 died (13%), 22 were discharged alive (12%) and 139 (76%) were still on the ICU on April 5th 2020. All patients received at least standard doses of thromboprophylaxis.

Their findings concluded that 31% incidence of thrombotic complications in ICU patients with COVID-19 infections is remarkably high.  Reinforcing the recommendation to strictly apply pharmacological thrombosis prophylaxis in all COVID-19 patients admitted to the ICU, and are strongly suggestive of increasing the prophylaxis towards high-prophylactic doses, even in the absence of randomized evidence.

”The 31% incidence of thrombotic complications in ICU patients with COVID-19 infections is remarkably high. The findings reinforce the recommendation to apply pharmacological thrombosis prophylaxis in all COVID-19 patients admitted to the ICU, and are strongly suggestive of increasing the prophylaxis towards high-prophylactic doses, even in the absence of randomized evidence.”

COVID-19 may predispose to both venous and arterial thromboembolism due to excessive inflammation, hypoxia, immobilisation and diffuse intravascular coagulation.

One important autopsy study was funded by the University Medical Center Hamburg-Eppendorf, Germany in which 27  Doctors contributed to the findings. Doctors performed autopsies on patients who had COVID-19 written as cause of death on their death certificates. Autopsies were performed at a single academic medical center, as mandated by the German federal state of Hamburg for 12 patients who died with a polymerase chain reaction–confirmed diagnosis of COVID-19. Complete autopsies were performed, including postmortem computed tomography and histopathologic and virologic analysis. Clinical data and medical course were evaluated.

According to the Results ”Median patient age was 73 years (range, 52 to 87 years), 75% of patients were male, and death occurred in the hospital (n = 10) or outpatient sector (n = 2). Coronary heart disease and asthma or chronic obstructive pulmonary disease were the most common comorbid conditions (50% and 25%, respectively).

                              ”Autopsy revealed deep venous thrombosis in 7 of 12 patients (58%) in whom venous thromboembolism was not suspected before death; pulmonary embolism was the direct cause of death in 4 patients. Postmortem computed tomography revealed reticular infiltration of the lungs with severe bilateral, dense consolidation, whereas histomorphologically diffuse alveolar damage was seen in 8 patients. In all patients, SARS–CoV-2 RNA was detected in the lung at high concentrations; viremia in 6 of 10 and 5 of 12 patients demonstrated high viral RNA titers in the liver, kidney, or heart.Postulating that COVID-19 is a vascular and hypoinfammatory disease has important implications for ongoing research. However, more evidence is needed to explore  vascular injury through biomarkers, imaging, and histology. If COVID-19 is indeed primarily a vascular disorder, early invasive mechanical ventilation should be initiated cautiously. Investigations should examine the impact of liberal versus restrictive invasive mechanical ventilation strategies.”

Treating  severe symptoms in patients with Coronavirus disease,  means doctors should be treating patients for chronic thrombotic disease, both in the venous and arterial circulations, due to excessive inflammation, platelet activation, endothelial dysfunction, and stasis.

Over 45 doctors from all over the world contributed to the Journal of the American College of Cardiology, another recent publication,  on ‘‘COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-up’. The evidence is accumulating that this is the conclusive modality for treating chronic symptoms of COVID-19 patients, hopefully rather than focusing on vaccines governments will consider supporting these concrete findings by funding available technology to care for patients without COVID-19  who have thrombotic disease caused by COVID-19.

Finally, while global medical journals are exponentially publishing similar findings- Medical Doctors advise that patients need prevention or care for their thrombotic disease during the COVID-19 pandemic.  Further suggestions are that Doctors should treat the chronic stages of this disease with anti-inflammatory therapies and medicines, read here some of these recommendations from doctors who have successful experience treating patience successfully with such treatments.


Related articles

Swedish Doctor explains COVID 19 successful treatments

Relationship between oxygen and 5G


Scientific Medical Journal References

  1. Thrombosis Research, Volume 191, July 2020, Pages 145-147
  2. Annals of Internal Medicine. Original Research-6 May 2020

3. Thieme Medical Journal –COVID-19-Related Severe Hypercoagulability in Patients Admitted to Intensive Care Unit for Acute Respiratory Failure

4. AHA Journals Will Complement Inhibition Be the New Target in Treating COVID-19–Related Systemic Thrombosis? Courtney M. Campbell, MD, PhD S Rami Kahwash, MD

5. Intensive Care Medical Journal – Facing COVID-19 in the ICU: vascular dysfunction, thrombosis, and dysregulated
infammation by Daniel E. Leisman, Cliford S. Deutschman and Matthieu Legrand* 2020 Springer-Verlag GmbH Germany, part of Springer Nature

6. ”COVID-19 and its implications for thrombosis and anticoagulation” in the medical journal Blood

7. The Journal of Thrombosis and Haemostasis Pathological evidence of pulmonary thrombotic phenomena in severe COVID‐19 Volume18, Issue6. June 2020. Pages 1517-1519.  International Society on Thrombosis and Haemostasis

8.  Complement associated microvascular injury and thrombosis in the pathogenesis of severe COVID-19 infection: a report of five cases. Journal of Translational Research, April, 2020

9. COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-up Journal of the American College of Cardiology April 2020

10. Arentz M, Yim E, Klaff L, et al. Characteristics and Outcomes of 21 Critically Ill Patients With COVID-19 in Washington State.
JAMA. 2020;10.1001/jama.2020.4326.

see the rest below and hundreds more in Google Scholar

Venous and arterial thromboembolic complications in COVID19 patients admitted to an academic hospital in Milan, Italy  C Sacco, B Alexia, MT Sandri, S Barco, H COVID… – Thrombosis research, 2020 – Elsevier
High risk of thrombosis in patients with severe SARS-CoV-2 infection: a multicenter prospective cohort study J Helms, C Tacquard, F Severac, I Leonard-Loran – Intensive care  2020 – Springer [PDF]
Large-vessel stroke as a presenting feature of Covid19 in the young TJ Oxley, J Mocco, S MajidiCP Kellner. England Journal of …, 2020 – Mass Medical Society [PDF]
Severe COVID19 infection associated with endothelial activation R Escher, N Breakey, B Lämmle – Thrombosis research, 2020 – [PDF]
Upsurge of deep venous thrombosis in patients affected by COVID19: preliminary data and possible explanations EM Marone, LF Rinaldi – Journal of Vascular Surgery: Venous and …, 2020 – Upsurge of deep venous thrombosis in patients affected by COVID19:
Coagulation disorders in coronavirus infected patients: COVID19, SARS-CoV-1, MERS-CoV and lessons from the past D GiannisIA Ziogas, P Gianni – Journal of Clinical Virology, 2020 – Elsevier [PDF]
Pulmonary embolism or pulmonary thrombosis in COVID19? Is the recommendation to use high-dose heparin for thromboprophylaxis justified? M Cattaneo, EM Bertinato, S Birocchi… – Thrombosis and …, 2020 – [PDF]
Incidence of venous thromboembolism in hospitalized patients with COVID19 . S Middeldorp, M Coppens et al [PDF]
ISTH interim guidance on recognition and management of coagulopathy in COVID19 J Thachil, N Tang, S Gando, A Falanga… – … of Thrombosis and …, 2020 – Wiley Online Library
Tissue plasminogen activator (tPA) treatment for COVID19 associated acute respiratory distress syndrome (ARDS): A case seriesJ Wang, N Hajizadeh, EE Moore
Pulmonary embolism in patients with COVID19: Time to change the paradigm of computed tomography DC Rotzinger, C Beigelman-Aubry, C von Garnier… – Thrombosis research, 2020 – Elsevier PDF]
High incidence of venous thromboembolic events in anticoagulated severe COVID19 patients JF Llitjos, M Leclerc, C Chochois… – … of Thrombosis and …, 2020 – Wiley Online Library PDF]
[PDF] Microvascular COVID19 lung vessels obstructive thromboinflammatory syndrome (MicroCLOTS): an atypical acute respiratory distress syndrome working … F Ciceri, L Beretta, AM Scandroglio, S Colombo… – Crit Care Resusc, 2020 –
Thrombotic complications of patients admitted to intensive care with COVID19 at a teaching hospital in the United Kingdom W Thomas, J Varley, A Johnston… – Thrombosis …, 2020 –
Thromboinflammation and the hypercoagulability of COVID19 JM Connors, JH Levy – Journal of Thrombosis and Haemostasis, 2020 – Wiley Online Library
Autopsy findings and venous thromboembolism in patients with COVID19: a prospective cohort study
D Wichmann, JP Sperhake… – Annals of Internal …, 2020 –
Lupus anticoagulant is frequent in patients with Covid19
I Harzallah, A Debliquis… – Journal of Thrombosis and …, 2020 – Wiley Online Library
ISTH interim guidance on recognition and management of coagulopathy in COVID19: A Comment
CD Barrett, HB Moore, MB Yaffe… – Journal of Thrombosis …, 2020 – Wiley Online Library
COVID19 Coagulopathy in Caucasian patients
H Fogarty, L Townsend, C Ni Cheallaigh… – British journal of …, 2020 – Wiley Online Library
[HTML] Coagulopathy and antiphospholipid antibodies in patients with Covid19 Y Zhang, M Xiao, S Zhang, P Xia, W Cao… – … England Journal of …, 2020 – Mass Medical Soc
[PDF] Suggestions for thromboprophylaxis and laboratory monitoring for in-hospital patients with COVID19 A Casini, L Alberio, A Angelillo-Scherrer… – Swiss Medical …, 2020 –
COVID19 complicated by acute pulmonary embolism Y Xie, X Wang, P Yang, S Zhang – Radiology: Cardiothoracic Imaging, 2020 –
Hypercoagulability of COVID19 patients in intensive care unit. A report of thromboelastography findings and other parameters of hemostasis M Panigada, N Bottino, P Tagliabue… – … of Thrombosis and …, 2020 – Wiley Online Library [PDF]
[PDF] Risk assessment of venous thromboembolism and bleeding in COVID19 patients J Xu, L Wang, L Zhao, F Li, J Liu, L Zhang, Q Li… – Respiratory …, 2020 –
Immune mechanisms of pulmonary intravascular coagulopathy in COVID19 pneumonia
D McGonagle, JS O’Donnell, K Sharif, P Emery… – The Lancet …, 2020 – Elsevier [HTML]
Complement as a target in COVID19?AM Risitano, DC Mastellos, M Huber-Lang… – Nature Reviews
Diagnosis, prevention, and treatment of thromboembolic complications in COVID19: report of the National Institute for Public Health of the Netherlands
M Oudkerk, HR Büller, D Kuijpers, N van Es… – Radiology, 2020 – pubs.rsna.or
Neutrophil extracellular traps in COVID19
Y Zuo, S Yalavarthi, H Shi, K Gockman, M Zuo… – JCI …, 2020 –

11 thoughts on “Hundreds of Medical Journals announce that COVID 19 symptoms should be treated as severe Thrombosis

Leave a Reply

Previous post A Recipe for Next Generation Warfare
Next post Trombosis grave: Cientos de revistas médicas anuncian que los síntomas de COVID 19 deben tratarse como trombosis grave
%d bloggers like this: